key: cord-0020367-habhc9vv authors: Bakovic, Allison; Bhalla, Nishank; Alem, Farhang; Campbell, Catherine; Zhou, Weidong; Narayanan, Aarthi title: Inhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3 date: 2021-08-03 journal: Viruses DOI: 10.3390/v13081533 sha: 585f8782587ece98955d1683b9d0fb4e1e8695e4 doc_id: 20367 cord_uid: habhc9vv Venezuelan equine encephalitis virus (VEEV) is a new world alphavirus and a category B select agent. Currently, no FDA-approved vaccines or therapeutics are available to treat VEEV exposure and resultant disease manifestations. The C-terminus of the VEEV non-structural protein 3 (nsP3) facilitates cell-specific and virus-specific host factor binding preferences among alphaviruses, thereby providing targets of interest when designing novel antiviral therapeutics. In this study, we utilized an overexpression construct encoding HA-tagged nsP3 to identify host proteins that interact with VEEV nsP3 by mass spectrometry. Bioinformatic analyses of the putative interactors identified 42 small molecules with the potential to inhibit the host interaction targets, and thus potentially inhibit VEEV. Three inhibitors, tomatidine, citalopram HBr, and Z-VEID-FMK, reduced replication of both the TC-83 strain and the Trinidad donkey (TrD) strain of VEEV by at least 10-fold in astrocytoma, astroglial, and microglial cells. Further, these inhibitors reduced replication of the related New World (NW) alphavirus Eastern equine encephalitis virus (EEEV) in multiple cell types, thus demonstrating broad-spectrum antiviral activity. Time-course assays revealed all three inhibitors reduced both infectious particle production and positive-sense RNA levels post-infection. Further evaluation of the putative host targets for the three inhibitors revealed an interaction of VEEV nsP3 with TFAP2A, but not eIF2S2. Mechanistic studies utilizing siRNA knockdowns demonstrated that eIF2S2, but not TFAP2A, supports both efficient TC-83 replication and genomic RNA synthesis, but not subgenomic RNA translation. Overall, this work reveals the composition of the VEEV nsP3 proteome and the potential to identify host-based, broad spectrum therapeutic approaches to treat new world alphavirus infections. Venezuelan equine encephalitis virus (VEEV) is a New World (NW) alphavirus that is naturally transmitted by mosquitoes and endemic in South America [1, 2] . However, epizootic outbreaks in the United States causing febrile and neurological illnesses in equids and humans have occurred periodically [3] . NW alphavirus infection can progress to encephalitis with a <1% case fatality rate for VEEV, with persistence of long-term neurological sequelae in survivors [3, 4] . VEEV is classified as a category B select pathogen by the National Institutes of Allergy and Infectious Diseases [5, 6] . Currently, there are no FDA-approved vaccines or therapeutics available for the treatment of exposure to VEEV and resultant disease manifestations. The live-attenuated vaccine strain of VEEV TC-83 is administered to military and at-risk personnel only, due to high reactogenicity concerns [7] . A pCAGGS-backbone plasmid expressing N-terminus HA-tagged nsP3 of the VEEV ZPC738 strain was previously described [35] . An empty control plasmid, Invitrogen™ pcDNA™ 3.1 (+) (Fisher Sci, V79020), was included in all over-expression transfections as a negative control. Next, 293T cells were seeded at 4 × 10 6 cells per T-175 culture flask 24 h prior to transfection. Then, 10 µg of plasmid DNA was transfected using Attractene transfection reagent (Qiagen, 301005, Germantown, MD, USA), according to the manufacturer's instructions. Flasks were incubated at 37 • C and 5% CO 2 for 24 h. ON-TARGETplus SMARTpool siRNA against Transcription Factor AP2 alpha (TFAP2A, ID: L-006348-02-0005) and against Eukaryotic Translation Initiation Factor 2 subunit 2 (eIF2S2, ID: L-011549-00-0005) was obtained from Dharmacon. ON-TARGETplus nontargeting control pool (Dharmacon, D-001810-10-05) was used as a negative control at a concentration of 50 nM. Next, 293T cells were seeded at 5 × 10 5 instructions. Mock-transfected cells, transfection with DharmaFECT reagent-only cells, and non-targeting control siRNA-treated cells were included as controls. Plates were incubated at 37 • C and 5% CO 2 for 72 h and subsequently infected, as described, for 24 h. For evaluation of viral genomic RNA translation, 293 T cells were either untreated or treated with 10 µM tomatidine diluted in culture media for 2 h. Five µg of the mutated stop codon TC-83 viral RNA was transfected using Attractene transfection reagent, according to the manufacturer's instructions. Plates were incubated at 37 • C and 5% CO 2 for 24 h. For preparation of whole cell lysates from infected or transfected cells, media were removed, and cells were washed twice with phosphate buffered saline (PBS, VWR, L0119-0500). Cells were lysed with cell lysis buffer (CLB, Cell Signaling Technology, 9803, Danvers, MA, USA) and were supplemented with 1mM phenylmethylsulfonyl fluoride (PMSF, Cell Signaling Technology, 8553S), 10 mM 1,4-Dithiothreitol (DTT) (Invitrogen, P2325), and phosphatase inhibitor cocktail (ThermoFisher, 78,420). Lysates were vortexed every 5 min (min) for 20 min, centrifuged at 10,000 rpm for 10 min at 4 • C, and supernatants were collected. The total protein for each sample was quantified against a standard curve of bovine serum albumin (BSA, Fisher Scientific, BP1600, Hampton, NH, USA) using Bradford reagent (VWR, E530-1L) and measured using a Beckman Coulter DTX 880 multimode plate reader. For non-immunoprecipitate (IP) samples, a 1:1 volume of 2× Laemmli buffer supplemented with 100mM DTT was added to lysate supernatants and boiled for 10 min. Two milligrams of total protein were incubated overnight at 4 • C with rotation using 2 µg mouse IgG3 isotype control (Abcam, 18394, Cambridge, UK) or anti-HA tag antibody (Abcam, ab 18181). Magnetic Dynabeads coated with protein G (FisherSci, 10-003-D) were washed with citrate phosphate buffer pH 5.0 (50 mM Tris-HCL pH 7.5, 120 mM NaCl, 5mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na 3 VO 4 , Protease cocktail tablet (Sigma-Aldrich, 11697498001, St. Louis, MO, USA) and added to the protein-antibody IP complexes. Rotation at room temperature proceeded for 40 min followed by 1x wash with TNE 100 + 0.1% NP-40, 1× wash with TNE 50 + 0.1% NP-40, and 2× wash with PBS. TNE buffers consisted of 100 mM Tris-HCl pH7.5 and 0.2 mM EDTA, with 100 mM NaCl for TNE 100 or 50 mM NaCl for TNE 50 . For Western blot imaging, Laemmli buffer supplemented with 100 mM DTT was added and beads were boiled for 10 min. For samples subjected to mass spectrometry, the last PBS wash was removed and Dynabeads were stored at −80 • C until processed for analysis. Boiled samples were resolved on 4-20% Tris-Glycine gels (ThermoFisher, XP04122), and transferred to polyvinyl difluoride (PVDF) membranes by wet transfer at 80 mA overnight at 4 • C. Membranes were blocked for 30 min at room temperature with 3% nonfat dried milk in Tris-buffered saline with 0.1% Tween-20 (TBS-T). Anti-HA tag antibody (Abcam, 18181) was diluted in 5% BSA in TBS-T at 1:1000 and incubated on membranes for 1 h at room temperature. Anti-TFAP2A antibody (Abcam, ab52222), anti-eIF2S2 (Abcam, ab184549), or anti-VEEV nsP2 antibody (KeraFast, EU015) were diluted in 5% BSA in TBS-T at 1:1000, 1:5000, or 1:1000, respectively, and incubated on individual membranes overnight at 4 • C. Membranes were washed thrice with TBS-T for 5 min and incubated with respective secondary HRP-conjugated antibodies (Fisher Sci, PI32460) diluted 1:10,000 in 3% non-fat dried milk in TBS-T at room temperature for 1 h. Membranes were washed twice for 5 min with TBS-T and twice for 5 min with TBS. Membranes were imaged with SuperSignal West Femto Maximum Sensitivity Substrate Kit (ThermoFisher, 34095) and Bio-Rad Molecular Imager ChemiDoc XRS system. For re-probing, membranes were stripped with mild stripping buffer containing 0.1 M glycine, 0.2 M NaCl, 0.1% Tween-20 at pH 2.5, and were blocked with 5% BSA in TBS-T for 30 min, incubated with HRP-conjugated anti-actin antibody (Abcam, ab49900), diluted to 1:10,000 in 5% BSA in TBS-T for 30 min, and reimaged with the ChemiDoc XRS system (Biorad, Hercules, CA, USA). ImageJ software was Viruses 2021, 13, 1533 5 of 24 used to quantitatively calculate band densities, signals were normalized to actin loading controls, and fold-change was calculated versus a mock-transfected control group. Full length blots are presented in Figure S1 . LC-MS/MS was performed in a similar manner as previously described [12, 36] . Briefly, immunoprecipitated Dynabeads were treated to 8M urea and disulfide bonds were reduced with 1M DTT and alkylated with iodacetamide. Following a trypsin digestion (ThermoFisher, 25200056) for 4 h at 37 • C, peptides were eluted with ZipTip purification (Millipore, Z720070, Rockville, MD, USA), and resuspended in H 2 O with 0.1% formic acid. Orbitrap Fusion tandem MS/MS with nanospray reverse-phase liquid chromatography (ThermoFisher) was performed. Full-scan mass spectra were acquired in Orbitrap over 300 to 2000 m/z with a 30,000 resolution followed with MS n scans by CID activation mode. The 3 most intense ions were selected for fragmentation using a 35 collision energy and activation at Q = 25 for 30 milliseconds. Dynamic exclusion and charge state rejection were enabled. Mass spectra were fitted against NCBI reference sequence AAB02516 or P27282 for the non-structural polyprotein sequence analysis with Sequest Bioworks software 3.3.1. (ThermoFisher). Ingenuity pathway analysis (IPA, Qiagen) was used to evaluate datasets obtained from mass spectrometry. Briefly, datasets obtained from IP-MS were evaluated for coverage of the nsP3 protein of interest, and host interactors common to the empty control vector samples were removed. The host proteins exclusive to nsP3 immunoprecipitation were inputted into IPA and evaluated for abundancy and repetition among the runs. IPA was used to generate a dataset identifying host interactors present in at least 2/4 or 2/3 MS runs, as well as chemicals and drugs that directly or indirectly targetted those host interactors. Tolcapone (S4021), etretinate (S4699), KU-60019 (S1570), tomatidine (S9430), and citalopram HBr (S4749) were obtained from Selleckchem. Z-VEID-FMK (ab142025) was obtained from Abcam. CCG-1423 (5233) was obtained from Tocris. SCH-23390 hydrochloride (HY-19545A) was obtained from MedChemExpress. N-Butylidenephthalide, (E) + (Z) (sc-279727) was obtained from Santa Cruz Biotechnology. Prior to use, all inhibitors were resuspended in dimethyl sulfoxide (DMSO), with the exception of n-Butylidenephthalide which was resuspended in ethanol. Cells were seeded in 96-well white plates 24 h prior to use at 1 × 10 4 cells per well, or 5 × 10 4 cells per well for 293T cells. Inhibitors were diluted to the indicated micromolar concentration (µM) in culture media. siRNA was diluted to the indicated nanomolar concentration (nM) using DharmaFECT Transfection Reagent and added to cells per manufacturer's instructions. Diluted inhibitors or siRNA were added to the cells and plates incubated at 37 • C and 5% CO 2 . At 24 h post-treatment (hpt), culture media were removed from the wells and cell viability was measured using CellTiterGlo ® Luminescent Cell Viability Assay per manufacturer's instructions (Promega, G7572, Madison, WI, USA). Luminescence was measured using a Beckman Coulter DTX 880 multimode plate reader. Cell viability for inhibitors was calculated as a percentage versus the DMSO vehicle control. Cell viability for siRNA was calculated as a percentage versus the mock-transfected control. Cells were seeded in 96-well plates 24 h prior at 1 × 10 4 cells per well. Inhibitors were diluted in culture media to the indicated concentrations, with the final concentration of DMSO ≤0.1%. Media were removed and cells were pretreated with media containing drug or 0.1% DMSO vehicle control for 2 h prior to infection. The virus was diluted in culture media to the indicated multiplicity of infection (MOI). At the time of infection, pretreatment was removed, and the viral inoculum was overlaid on cells for 1 h. After 1 h, virus inoculum was removed, cells were washed 1× with PBS, and media containing inhibitor was added to cells. For time of addition infections, fresh media were added after the removal of viral inoculum until the indicated time point post-infection, at which time the diluted inhibitor was added. A 2-h inhibitor pretreatment was included as an internal control. Cells were incubated at 37 • C and 5% CO 2 for the indicated duration. At the indicated time point post-infection (hpi), viral supernatants were collected and/or cellular lysates were obtained, and all samples were stored at −80 • C prior to further use. Vero cells were seeded in 12-well plates at a density of 2.5 × 10 5 cells per well and incubated for 24 h. Infection supernatants were serially diluted 10-fold in culture media and overlaid on cells for 1 h. Wells were covered with Eagle's minimum essential medium (without phenol red, FisherSci, 67-008-6), supplemented with 5% FBE, nonessential amino acids (FisherSci, 11-140-050), 1 mM sodium pyruvate (VWR, 45000-710), 2 mM L-glutamine, 20 U/mL penicillin, and 20µg/mL streptomycin mixed 1:1 with 0.6% agarose (ThermoFisher, 16500100). At 48 hpi, cells were fixed with 10% formaldehyde for at least 1 h. The medium was removed and stained with a 1% crystal violet in 20% ethanol solution. Next, 293T cells were untreated or treated with 10 µM tomatidine diluted in culture media for 2 h. Cells were infected with the nLuc-TaV expressing TC-83 virus at MOI 0.1 as described and incubated for 24 h. Cellular lysates were obtained using 1× Passive Lysis Buffer (Promega, E1941) and the Nano-Glo Luciferase Assay System was used to quantify subgenomic translation by measuring luciferase activity per manufacturer's instructions. An aliquot of cellular lysates were mixed with Bradford reagent (Bio-Rad, 5000006, California, USA), according to the manufacturer's instructions, and a standard curve for total protein was established, as previously described [12] . Mock infected cells were used to establish limits of detection, and luminescence and absorbance were measured using a DTX 880 multimode plate reader (Beckman Coulter, Indianapolis, IN, USA). Luciferase levels were normalized to total protein (RLU/µg). At the indicated time points, cells were washed with PBS and lysed with TRIzol Reagent (Invitrogen, Waltham, MA, USA). Intracellular RNA was extracted with a Directzol Miniprep RNA kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions, and stored at −80 • C prior to further use. All primers and probes were designed and obtained from Integrated DNA Technologies (IDT) using the PrimerQuest Tool. Primer/probe sets targeting the capsid and nsP3 region of the viral genome, which have previously been described [12] . Briefly, the sets contained a double-quenched ZEN/IBFQ probe with a 6-FAM fluorescent dye attachment at the 5 end. A 18S rRNA endogenous control primer/probe set was obtained from Ther-moFisher (4333760T). Amplification of the negative-strand TC-83 RNA has previously been described [12] . cDNA specific to negative-strand TC-83 RNA was generated using a T7 promoter sequence tagged at the 5 end of the negative-strand and the high-capacity cDNA reverse transcription kit (ThermoFisher, 4368814), according to the the manufacturer's instructions. Semi-quantitative RT-PCR has been previously described for measuring levels of capsid, nsP3, and 18S [12] and used thermal cycling conditions adapted from Verso 1-step RT-qPCR kit (ThermoFisher, AB4101C), according to the the manufacturer's instructions. Amplification of the negative-strand RNA has been previously described [12] and used thermal cycling conditions adapted from PowerUp SYBR Green (ThermoScientific, A25742) according to the the manufacturer's instructions. All reactions were amplified using StepOnePlus™ Real Time PCR system and no template cDNA controls and mock infections were included for all analyses to establish the limits of detection. Quantification for qRT-PCR was calculated using a standard curve based on threshold cycle (Ct) values. Semi-quantitative RT-PCR values were calculated using the ∆∆Ct method [37] with viral RNA normalized to 18S levels. All graphs represent the mean ± SD for all data obtained. Prism 7 (Graph Pad) was used for all statistical analyses and significance was determined using one-way ANOVA with Dunnett's post test unless otherwise stated. Statistical significance values are indicated using asterisk for * p < 0.0332, ** p < 0.0021, *** p< 0.0002, **** p < 0.0001, and ns for not significant. Prism 7 was used for curve fitting and predicting CC 50 values using nonlinear regression with least squares (ordinary) fit and the log(inhibitor) vs. response variable slope (four parameters) equation. R 2 values for goodness of fit were acceptable >0.85. Alphavirus nsP3 appears to act as a hub for host protein interactions that support efficient viral replication and can drive cell specific preferences for host-protein interactions among different alphaviruses [9, 23, 24] . To date, 23 host-protein interactions with VEEV nsP3 have been identified [9, 12, 38, 39] . A mass spectrometry approach was employed in order to an effort to expand the reported nsP3:host protein interactome and utilize those host protein targets to identify small molecule inhibitors with antiviral activity against alphaviruses. As the first step, 293 T cells were transfected with an overexpression plasmid encoding HA-tagged VEEV nsP3 at the N-terminus. Total protein lysates obtained from the transfected cells were used for immunoprecipitation (IP) using a HA antibody to enrich for nsP3-interacting host partners. Expression of nsP3 in transfected cells was confirmed by Western blot ( Figure 1A , left panel), and a Western blot using IP samples ( Figure 1A , right panel) confirmed the specificity of the HA-tag IP pulldown. HA-IP samples from both HA-nsP3 and the pcDNA empty control vector transfections (negative control) were subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS). Spectra from MS runs 1-2 ( Figure 1B) were fitted against the nonstructural polyprotein for the wild-type Trinidad donkey (TrD) strain. Spectra from MS runs 3-7 were fitted against the specific amino acids for nsP3 of the VEEV nonstructural polyprotein precursor ( Figure 1B ). Figure 1B displays the percentage of nsP3 protein covered by the number of peptides detected as well as the protein score (Score A SEQUEST HT), as measured by the individual scores of the peptides for a marker of protein identification. Total protein hits for the 7 MS runs were further evaluated to obtain interactors and inhibitors of interest ( Figure 1C ). Briefly, MS data were processed to remove host interactors identified in the HA-pcDNA IP from the HA-nsP3 IP samples in order to eliminate background hits and obtain host proteins that specifically interact with VEEV nsP3. These putative host interactors were evaluated using Ingenuity Pathways Analysis (IPA) to obtain a list of host proteins detected across multiple MS runs as well as inhibitors targeting the activity of these proteins. MS runs 1-4 were analyzed together and host proteins present in at least 2 of 4 runs were selected. Similarly, MS runs 5-7 were analyzed together and host proteins present in at least 2 of 3 runs were selected. The two sets of MS runs were analyzed independently in order to expand detection of potential host proteins that may be interacting with VEEV nsP3. In total, 160 putative host interactors with VEEV nsP3 (Supplementary Table S1 ) were identified along with 42 inhibitors targeting these host proteins as identified by IPA (Supplementary Table S2 ). The inhibitors prioritized by IPA were further analyzed in the context of published literature and the inhibitor list was narrowed to nine candidates for in vitro analyses of inhibitory potential ( Figure 1D ). These inhibitors were selected based on previous efficacy studies with related alphaviruses or other positive-sense RNA viruses, or if their predicted host target suggested a proviral role for replication. 7 MS runs were further evaluated to obtain interactors and inhibitors of interest ( Figure 1C ). Briefly, MS data were processed to remove host interactors identified in the HA-pcDNA IP from the HA-nsP3 IP samples in order to eliminate background hits and obtain host proteins that specifically interact with VEEV nsP3. These putative host interactors were evaluated using Ingenuity Pathways Analysis (IPA) to obtain a list of host proteins detected across multiple MS runs as well as inhibitors targeting the activity of these proteins. MS runs 1-4 were analyzed together and host proteins present in at least 2 of 4 runs were selected. Similarly, MS runs 5-7 were analyzed together and host proteins present in at least 2 of 3 runs were selected. The two sets of MS runs were analyzed independently in order to expand detection of potential host proteins that may be interacting with VEEV nsP3. In total, 160 putative host interactors with VEEV nsP3 (Supplementary Table S1 ) were identified along with 42 inhibitors targeting these host proteins as identified by IPA (Supplementary Table S2 ). The inhibitors prioritized by IPA were further analyzed in the context of published literature and the inhibitor list was narrowed to nine candidates for in vitro analyses of inhibitory potential ( Figure 1D ). These inhibitors were selected based on previous efficacy studies with related alphaviruses or other positive-sense RNA viruses, or if their predicted host target suggested a proviral role for replication. Figure 1 . Mass spectrometry identified putative host interactors with VEEV nsP3 and potential antivirals. Then, 293T cells were transfected with a pcDNA 3.1 (+) empty control plasmid or a pCAGGS plasmid expressing N-terminus HA-tagged nsP3 of the ZPC738 VEEV strain. Next, 24 hpt, lysates were subjected to immunoprecipitation with anti-HA tag antibody or IgG3 isotype control antibody. Expression and immunoprecipitation of HA-nsP3 was confirmed by Western blot (A) and six independent immunoprecipitated samples were subjected to Fusion Orbitrap mass spectrometry (B), as described in Materials and Methods. Western blot and immunoprecipitations are representative of six independent experiments (n = 6). Mass spectra were fitted against the NCBI reference sequence AAB02516 or P27282 for the non-structural polyprotein of VEEV. (C) Schematic of data analysis by Ingenuity Pathway Analysis. Host proteins identified by mass spectrometry runs were analyzed for abundancy and identification of canonical pathways, networks, and inhibitors. (D) A list of small molecule inhibitors were identified using IPA for efficacy studies. Figure 1 . Mass spectrometry identified putative host interactors with VEEV nsP3 and potential antivirals. Then, 293T cells were transfected with a pcDNA 3.1 (+) empty control plasmid or a pCAGGS plasmid expressing N-terminus HA-tagged nsP3 of the ZPC738 VEEV strain. Next, 24 hpt, lysates were subjected to immunoprecipitation with anti-HA tag antibody or IgG3 isotype control antibody. Expression and immunoprecipitation of HA-nsP3 was confirmed by Western blot (A) and six independent immunoprecipitated samples were subjected to Fusion Orbitrap mass spectrometry (B), as described in Materials and Methods. Western blot and immunoprecipitations are representative of six independent experiments (n = 6). Mass spectra were fitted against the NCBI reference sequence AAB02516 or P27282 for the non-structural polyprotein of VEEV. (C) Schematic of data analysis by Ingenuity Pathway Analysis. Host proteins identified by mass spectrometry runs were analyzed for abundancy and identification of canonical pathways, networks, and inhibitors. (D) A list of small molecule inhibitors were identified using IPA for efficacy studies. The toxicity of selected inhibitors was assessed at multiple concentrations in U-87MG astrocytes [40, 41] . Cell viability upon inhibitor treatment was evaluated against a 0.1% DMSO solvent control and cell survival of >90% was considered acceptable (Figure 2A) . Notably, tolcapone, Eetretinate, n-Butylidenephthalide, Z-VEID-FMK, and citalopram HBr were nontoxic at all concentrations tested up to 100 µM. KU-60019, tomatidine, and CCG-1423 exhibited toxicity at concentrations ≥50 µM, and R-SCH-23390 HCl displayed toxicity at a 50 µM concentration. To determine the ability of these small molecules to reduce viral replication, U-87MG cells were pretreated with nontoxic concentrations for each of the nine inhibitors for 2 h and infected with VEEV TC-83 at MOI 0.1 ( Figure 2B ). Supernatants were collected at 24 hpi and evaluated for infectious titers by plaque assay ( Figure 2C ). Etretinate and KU-60019 failed to inhibit production of particle-forming units (PFU/mL) (ns, p < 0.0332, respectively). Tolcapone, R-SCH-23390, n-Butylidenephthalide, and CCG-1423 reduced TC-83 replication < 10-fold (p < 0.0001) compared to replication in DMSOtreated cells. In contrast, tomatidine reduced TC-83 replication by 11-fold (p < 0.0001), citalopram HBr by 87-fold (p < 0.0001), and Z-VEID-FMK by 128-fold (p < 0.0001) compared to replication in DMSO treated cells. The inhibitors displaying > 10-fold inhibition of VEEV TC-83 replication were chosen to further expand the in vitro efficacy studies. Notably, tolcapone, Eetretinate, n-Butylidenephthalide, Z-VEID-FMK, and citalopram HBr were nontoxic at all concentrations tested up to 100 μM. KU-60019, tomatidine, and CCG-1423 exhibited toxicity at concentrations ≥50 μM, and R-SCH-23390 HCl displayed toxicity at a 50 μM concentration. To determine the ability of these small molecules to reduce viral replication, U-87MG cells were pretreated with nontoxic concentrations for each of the nine inhibitors for 2 h and infected with VEEV TC-83 at MOI 0.1 ( Figure 2B ). Supernatants were collected at 24 hpi and evaluated for infectious titers by plaque assay ( Figure 2C ). Etretinate and KU-60019 failed to inhibit production of particle-forming units (PFU/mL) (ns, p < 0.0332, respectively). Tolcapone, R-SCH-23390, n-Butylidenephthalide, and CCG-1423 reduced TC-83 replication < 10-fold (p < 0.0001) compared to replication in DMSO-treated cells. In contrast, tomatidine reduced TC-83 replication by 11-fold (p < 0.0001), citalopram HBr by 87-fold (p < 0.0001), and Z-VEID-FMK by 128-fold (p < 0.0001) compared to replication in DMSO treated cells. The inhibitors displaying > 10-fold inhibition of VEEV TC-83 replication were chosen to further expand the in vitro efficacy studies. To evaluate cell type independence, the antiviral activity of tomatidine, citalopram HBr, and Z-VEID-FMK against VEEV was quantified in additional cells of the central nervous system (CNS). Human microglial cells (HMC3) and astroglial cells (SVGp12), with macrophage and fibroblast morphologies were chosen as these cells retain neuroinflammatory properties in vitro and are susceptible to VEEV infection [42] . Inhibitor associated toxicity was quantified in both cell lines by measuring cell viability against the DMSO solvent control ( Figure 3A ,B). Tomatidine and citalopram HBr were nontoxic at 10 μM (ns), whereas Z-VEID-FMK was toxic at 20 μM in HMC3 cells (p < 0.0001) and toxic at 10 μM in SVGp12 cells (p < 0.0021) ( Figure 3A ). The nontoxic concentration of each drug was subsequently used to test for inhibitory efficacy against TC-83 ( Figure 3C ,D). SVGp12 and HMC3 cells were pretreated with two concentrations of each drug and infected with TC-83 (MOI 0.1) and viral supernatants were evaluated for infectious titers at 24 hpi by plaque assay (Figure 3C,D) . Tomatidine displayed a 4.5-fold decrease in replication levels at 10 μM (p < 0.0002), whereas citalopram HBr displayed a 10-fold decrease in replication levels (p < 0.0001) when compared to DMSO-treated SVGp12 cells ( Figure 3C ). All other treatment conditions displayed < two-fold reduction or no reduction in TC-83 replication levels in SVGp12 cells (p < 0.0332, ns). However, treatment of HMC3 cells with 10μM or 20 μM tomatidine ( Figure 3D ) reduced TC-83 titers by four-fold and 29-fold, respectively, in comparison with the DMSO control (p < 0.0001). Furthermore, 10 μM and 20 μM concentrations of citalopram HBr reduced TC-83 replication in HMC3 cells by four-fold and three-fold, respectively, in comparison to the DMSO control (p < 0.0001). Z-VEID-FMK treatment reduced TC-83 replication in HMC3 cells by three-fold and five-fold at 5 μM Cells were infected with TC-83 at MOI of 0.1 in triplicate for 1 h. Conditioned media containing inhibitor was replaced after removal of the virus. At 24 hpi, viral supernatants were collected and evaluated by plaque assay, as described in Materials and Methods. Graph represents data from two independent experiments performed in triplicate (n = 6). * p < 0.0332, **** p < 0.0001, ns, not significant. To evaluate cell type independence, the antiviral activity of tomatidine, citalopram HBr, and Z-VEID-FMK against VEEV was quantified in additional cells of the central nervous system (CNS). Human microglial cells (HMC3) and astroglial cells (SVGp12), with macrophage and fibroblast morphologies were chosen as these cells retain neuroinflammatory properties in vitro and are susceptible to VEEV infection [42] . Inhibitor associated toxicity was quantified in both cell lines by measuring cell viability against the DMSO solvent control ( Figure 3A ,B). Tomatidine and citalopram HBr were nontoxic at 10 µM (ns), whereas Z-VEID-FMK was toxic at 20 µM in HMC3 cells (p < 0.0001) and toxic at 10 µM in SVGp12 cells (p < 0.0021) ( Figure 3A ). The nontoxic concentration of each drug was subsequently used to test for inhibitory efficacy against TC-83 ( Figure 3C ,D). SVGp12 and HMC3 cells were pretreated with two concentrations of each drug and infected with TC-83 (MOI 0.1) and viral supernatants were evaluated for infectious titers at 24 hpi by plaque assay (Figure 3C,D) . Tomatidine displayed a 4.5-fold decrease in replication levels at 10 µM (p < 0.0002), whereas citalopram HBr displayed a 10-fold decrease in replication levels (p < 0.0001) when compared to DMSO-treated SVGp12 cells ( Figure 3C ). All other treatment conditions displayed < two-fold reduction or no reduction in TC-83 replication levels in SVGp12 cells (p < 0.0332, ns). However, treatment of HMC3 cells with 10µM or 20 µM tomatidine ( Figure 3D ) reduced TC-83 titers by four-fold and 29-fold, respectively, in comparison with the DMSO control (p < 0.0001). Furthermore, 10 µM and 20 µM concentrations of citalopram HBr reduced TC-83 replication in HMC3 cells by four-fold and three-fold, respectively, in comparison to the DMSO control (p < 0.0001). Z-VEID-FMK treatment reduced TC-83 replication in HMC3 cells by three-fold and five-fold at 5 µM and 10 µM, respectively (p < 0.0001). Collectively, tomatidine and Z-VEID-FMK exhibited antiviral activity against VEEV TC-83 in HMC3 cells in a dose-dependent manner, whereas citalopram HBr displayed comparable inhibition at both tested concentrations. 021, 13, x FOR PEER REVIEW 11 of 24 and 10 μM, respectively (p < 0.0001). Collectively, tomatidine and Z-VEID-FMK exhibited antiviral activity against VEEV TC-83 in HMC3 cells in a dose-dependent manner, whereas citalopram HBr displayed comparable inhibition at both tested concentrations. , and viral supernatants were collected and evaluated by plaque assay, as described in Materials and Methods. Graph represents data from two independent experiments performed in triplicate (n = 6). * p < 0.0332, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001, ns, not significant. SI values are expressed as the ratio of the cytotoxic concentration, at which 50% cellular death occurs (CC50) to the effective concentration, and at which 50% reduction in viral load is observed following inhibitor treatment (EC50) [43] . U-87MG cells were used to determine SI values for tomatidine, citalopram HBr, and Z-VEID-FMK. Citalopram HBr is FDA-approved, exhibiting nanomolar potency while inhibiting apoptotic activity in vitro [44, 45] . Z-VEID-FMK is a well-documented caspase-6 inhibitor demonstrating inhibition of fas-induced apoptosis at nanomolar concentrations [46, 47] . Cell viability was measured for each inhibitor at 24 h post-treatment ( Figure 4A ). Tomatidine displayed a CC50 value of 175 μM while citalopram HBr and Z-VEID-FMK were nontoxic at most concentrations tested. To determine IC50 values, U-87MG cells were pretreated for 2 h, infected with TC-83 virus, and viral supernatants were evaluated by plaque assay at 24 hpi ( Figure 4B ). In addition, 50% inhibition of TC-83 replication was observed at 2.5 μM for , and viral supernatants were collected and evaluated by plaque assay, as described in Materials and Methods. Graph represents data from two independent experiments performed in triplicate (n = 6). * p < 0.0332, ** p < 0.0021, *** p < 0.0002, **** p < 0.0001, ns, not significant. SI values are expressed as the ratio of the cytotoxic concentration, at which 50% cellular death occurs (CC 50 ) to the effective concentration, and at which 50% reduction in viral load is observed following inhibitor treatment (EC 50 ) [43] . U-87MG cells were used to determine SI values for tomatidine, citalopram HBr, and Z-VEID-FMK. Citalopram HBr is FDAapproved, exhibiting nanomolar potency while inhibiting apoptotic activity in vitro [44, 45] . Z-VEID-FMK is a well-documented caspase-6 inhibitor demonstrating inhibition of fasinduced apoptosis at nanomolar concentrations [46, 47] . Cell viability was measured for each inhibitor at 24 h post-treatment ( Figure 4A ). Tomatidine displayed a CC 50 value of 175 µM while citalopram HBr and Z-VEID-FMK were nontoxic at most concentrations tested. To determine IC 50 values, U-87MG cells were pretreated for 2 h, infected with TC-83 virus, and viral supernatants were evaluated by plaque assay at 24 hpi ( Figure 4B ). In addition, 50% inhibition of TC-83 replication was observed at 2.5 µM for tomatidine, 1 µM for citalopram HBr, and 0.5 µM for Z-VEID-FMK ( Figure 4C ). The resulting SI value for tomatidine was calculated as 70. Because a 50% cytotoxicity value was not determined for citalopram HBr and Z-VEID-FMK, a nonlinear regression curve analysis with least squared (ordinary) fit predicted CC 50 To determine the steps of the VEEV replication cycle affected by tomatidine, citalopram HBr, or Z-VEID-FMK treatment, viral replication kinetics and levels of positive and negative-sense viral RNA strands in infected cells were quantified following pretreatment or post-treatment with these inhibitors. First, the replication levels of TC-83 in U-87MG cells were measured at 6, 12, and 24 hpi after a 2-h pretreatment with each drug and subsequent infection at MOI 0.1 ( Figure 5A ). At each time point post-infection, viral supernatants were evaluated for infectious titers by plaque assay ( Figure 5B ) and intracellular lysates were obtained to quantify the positive-and negative-RNA strands by qRT-PCR and semi-quantitative RT-PCR, respectively ( Figure 5C ). At all time points, infectious particle production was inhibited for all three inhibitors tested ( Figure 5B ). Tomatidine reduced plaque formation as time points post-infection increased with a 55-fold, 9-fold, and 21-fold reduction observed at 6, 12, and 24 hpi, respectively, as compared to the To determine the steps of the VEEV replication cycle affected by tomatidine, citalopram HBr, or Z-VEID-FMK treatment, viral replication kinetics and levels of positive and negative-sense viral RNA strands in infected cells were quantified following pre-treatment or post-treatment with these inhibitors. First, the replication levels of TC-83 in U-87MG cells were measured at 6, 12, and 24 hpi after a 2-h pretreatment with each drug and subsequent infection at MOI 0.1 ( Figure 5A ). At each time point post-infection, viral supernatants were evaluated for infectious titers by plaque assay ( Figure 5B ) and intracellular lysates were obtained to quantify the positive-and negative-RNA strands by qRT-PCR and semi-quantitative RT-PCR, respectively ( Figure 5C ). At all time points, infectious particle production was inhibited for all three inhibitors tested ( Figure 5B ). Tomatidine reduced plaque formation as time points post-infection increased with a 55-fold, 9-fold, and 21-fold reduction observed at 6, 12, and 24 hpi, respectively, as compared to the DMSO control ( Figure 5B ). However, a more consistent and progressive inhibition of intracellular positivesense RNA synthesis was observed at 10-fold, 45-fold, and 124-fold for 6, 12, and 24 hpi, respectively ( Figure 5C ). Citalopram HBr reduced plaque production by 72-fold, 54-fold, and 176-fold at 6, 12, and 24 hpi, respectively, as compared to the DMSO control ( Figure 5B ). The reduction in positive-sense RNA synthesis was inhibited variably upon citalopram HBr treatment, by 21-fold,~10,000-fold, and 1000-fold at 6, 12, 24 hpi, respectively ( Figure 2C ). Z-VEID-FMK reduced plaque production as time points post-infection increased with a 44-fold, 53-fold, and 74-fold inhibition observed at 6, 12, 24 hpi, respectively, as compared to the DMSO control ( Figure 5B) , whereas, positive-sense RNA was reduced at 6, 12, and 24 hpi by 39-fold, 606-fold, and 110-fold, respectively, as compared to the DMSO control ( Figure 5C ). Collectively, citalopram HBr and Z-VEID-FMK reduce TC-83 plaque and positive-sense RNA production across all time points post-infection ( Figure 5B )., In contrast to the large inhibition of positive-sense RNA levels observed, all three inhibitors reduced negative-sense RNA synthesis by